---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-251807"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2022-09-27T23:59:59+00:00"
generated_at: "2026-06-23T07:17:24.064335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Equillium reports interim itolizumab data in LN: 50% CR at week 28, 67% >80% UPCR reduction

## Summary
- Baseline mean UPCR 5.8 g/g; 13 subjects enrolled, 11 reached week 12, 6 reached week 28/EOS.
- At week 28: 3/6 (50%) achieved complete response (UPCR <0.7 g/g); 2/6 (33%) partial response.
- 4/6 (67%) achieved >80% reduction in UPCR; average 60% reduction across all dosed subjects.
- No drug-related serious adverse events or treatment discontinuations; steroid tapered to <7.5 mg/day.
- Top-line Type B data expected mid-2023; pending Metacrine acquisition also noted in filing.

## SEC filing metadata
- accession: 0001193125-22-251807
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2022-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312522251807/0001193125-22-251807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312522251807/d383524d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-251807
- JSON: https://secwatch.observer/filing/0001193125-22-251807.json
- Plain text: https://secwatch.observer/filing/0001193125-22-251807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.